<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504347</url>
  </required_header>
  <id_info>
    <org_study_id>730901</org_study_id>
    <secondary_id>2010-023384-18</secondary_id>
    <nct_id>NCT01504347</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Lyme Vaccine Study</brief_title>
  <official_title>Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Innovations GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Section 1:&#xD;
&#xD;
      The purpose of the study is to obtain safety and immunogenicity data of different dose levels&#xD;
      of a multivalent recombinant OspA Lyme Borreliosis (mv rOspA LB) Vaccine with and without&#xD;
      adjuvant in seronegative healthy adults aged 18 to 70 years. The outcome shall provide the&#xD;
      basis for dose/formulation selection for Section 2 of the study.&#xD;
&#xD;
      Section 2:&#xD;
&#xD;
      An additional purpose of the study is to evaluate the safety and immunogenicity of the&#xD;
      optimal dose(s)/formulation of the mv rOspA LB Vaccine in a larger population of seronegative&#xD;
      and seropositive healthy subjects aged 18 to 70 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2011</start_date>
  <completion_date type="Actual">February 28, 2014</completion_date>
  <primary_completion_date type="Actual">September 13, 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody response to the vaccine</measure>
    <time_frame>28 days after the third vaccination (= Day 85)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of injection site and systemic reactions</measure>
    <time_frame>Within 7 days after each vaccination (i.e. Days 8, 36 and 64)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response</measure>
    <time_frame>At baseline, 28 days after each vaccination (i.e. Days 29, 57 and 85), 180 and 270 days after the first vaccination (Day 181, Day 271) and 180 days after the booster vaccination (Day 361 or Day 451 - 546)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold increase in antibody titer compared to baseline</measure>
    <time_frame>28 days after each vaccination, 180 and 270 days after the first vaccination and 180 days after the booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate (at least 4-fold increase of each rOspA type-specific Immunoglobulin G (IgG) titer) as compared to baseline</measure>
    <time_frame>28 days after each vaccination, 180 and 270 days after the first vaccination and 180 days after the booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>28 days after each vaccination and during entire study period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1630</enrollment>
  <condition>Prophylaxis of Lyme Borreliosis</condition>
  <arm_group>
    <arm_group_label>Primary vaccination in seronegative subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Booster vaccination in seronegative subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary + booster vacc. (seronegative + seropositive subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multivalent recombinant OspA Lyme Borreliosis Vaccine</intervention_name>
    <description>Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)</description>
    <arm_group_label>Primary vaccination in seronegative subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multivalent recombinant OspA Lyme Borreliosis Vaccine</intervention_name>
    <description>Booster vaccination 9-12 months after first vaccination in Section 1 subjects</description>
    <arm_group_label>Booster vaccination in seronegative subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multivalent recombinant OspA Lyme Borreliosis Vaccine</intervention_name>
    <description>3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)</description>
    <arm_group_label>Primary + booster vacc. (seronegative + seropositive subjects)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Subject is 18 to 70 years old at the time of screening&#xD;
&#xD;
          -  Subject has an understanding of the study, agrees to its provisions, and gives written&#xD;
             informed consent prior to study entry&#xD;
&#xD;
          -  Subject is generally healthy, as determined by the investigator's clinical judgment&#xD;
             through collection of medical history and the performance of a physical examination&#xD;
&#xD;
          -  If female of childbearing potential, presents with a negative urine pregnancy test,&#xD;
             and agrees to employ adequate birth control measures for the duration of the study&#xD;
&#xD;
        Additional inclusion criterion for seropositive subjects in Section 2 only:&#xD;
&#xD;
        - Subject is seropositive for Borrelia burgdorferi sensu lato (s.l.) antibodies at study&#xD;
        entry&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a physician-diagnosed chronic illness related to Lyme borreliosis (LB) or&#xD;
             active LB&#xD;
&#xD;
          -  Subject has been treated for LB with antibiotics within 3 months of study entry&#xD;
&#xD;
          -  Subject had a tick bite within 3 weeks prior to screening or first vaccination&#xD;
&#xD;
          -  Subject has a history or active infection with Babesia microti (babesiosis) or&#xD;
             Anaplasma phagocytophilum (ehrlichiosis)&#xD;
&#xD;
          -  Subject currently has or has a history of significant cardiovascular, respiratory&#xD;
             (including asthma), metabolic, neurological, hepatic, rheumatic, autoimmune,&#xD;
             hematological, gastrointestinal or renal disorder&#xD;
&#xD;
          -  Subject has clinically significant abnormal laboratory values at screening&#xD;
&#xD;
          -  Subject currently has or has a history of immunodeficiency&#xD;
&#xD;
          -  Subject tests positive for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg) or hepatitis C virus (HCV)&#xD;
&#xD;
          -  Subject has a disease or is currently undergoing a form of treatment or was undergoing&#xD;
             a form of treatment within 30 days prior to study entry that could be expected to&#xD;
             influence immune response.&#xD;
&#xD;
          -  Subject has a history of anaphylaxis or severe allergic reactions&#xD;
&#xD;
          -  Subject has received any live vaccine within 4 weeks or inactivated vaccine within 2&#xD;
             weeks prior to vaccination in this study&#xD;
&#xD;
          -  Subject is pregnant or lactating at the time of study enrollment&#xD;
&#xD;
        Additional exclusion criterion for subjects in Section 1 and seronegative subjects in&#xD;
        Section 2:&#xD;
&#xD;
        - Subject is seropositive for Borrelia burgdorferi sensu lato (s.l.) antibodies at study&#xD;
        entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna, Dept. of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Reisemedizin (Center for Travel Medicine)</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berliner Centrum für Reise- und Tropenmedizin GmbH (BCRT)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GWT-TUD GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Cutanis (Dermatologist)</name>
      <address>
        <city>Freiburg</city>
        <zip>79117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis (Internal Medicine Group Practice)</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innomed Dr. Naudts Klinische Forschung</name>
      <address>
        <city>Rodgau</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Abtlg. Tropenmedizin</name>
      <address>
        <city>Tübingen</city>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Borrelia Infections</mesh_term>
    <mesh_term>Lyme Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

